• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Intersect ENT to acquire Fiagon for $71.1M

Intersect ENT to acquire Fiagon for $71.1M

September 15, 2020 By Sean Whooley

Intersect ENT (NSDQ:XENT) announced today that it entered into an agreement to acquire Fiagon AG Medical Technologies for $71.1 million.

The $71.1 million (€60 million) cash deal will see Intersect ENT make an initial $17.8 million (€15 million) payment at the time of closing and further $17.8 (€15 million) annual payments over the following three years.

Menlo Park, Calif.-based Intersect ENT, an ear, nose and throat condition treatment developer, expects the acquisition to close within 30 days, subject to customary closing conditions.

Goldman Sachs & Co. LLC is acting as exclusive financial advisor to Intersect ENT and Cooley LLP and Fieldfisher (Germany) LLP are acting as its legal counsel. Oppenheimer is acting as financial advisor to Fiagon and Morrison & Foerster LLP is acting as its legal counsel.

Fiagon develops proprietary surgical navigation systems that support both routine and complex ENT procedures, enabling surgeons to track the full range of instruments deployed during a functional endoscopic sinus surgery procedure, according to a news release.

The Hennigsdorf, Germany-based company’s instruments are tip-tracked and do not require calibration in an effort to increase intuitiveness and ease of use.

In the release, Fiagon president & CEO Dr. Kai Desinger said the companies expect that the combination of Intersect ENT’s product offerings and sales force allows the two to jointly leverage innovation and commercialization.

“Fiagon represents a strategic technology acquisition for Intersect ENT that immediately expands our portfolio of ENT product offerings, complements our existing Propel and Sinuva sinus implants and helps extend our geographic reach,” Intersect ENT president & CEO Thomas West said in the release. “Fiagon develops, and commercializes globally, innovative electromagnetic surgical navigation systems and an associated suite of surgical tools targeted to the ENT surgical space. In addition, in August of 2020 Fiagon received U.S. FDA 510(k) clearance for a navigable sinuplasty balloon.

“The combination of the Intersect ENT and Fiagon portfolios allows Intersect ENT to deliver more comprehensive surgical solutions across the sinusitis care continuum regardless of site of care. This deal is consistent with our intention to provide comprehensive value-added and evidenced-based solutions for ENT physicians and the patients they serve.”

$1 = €0.843873

Filed Under: Business/Financial News, Featured, Mergers & Acquisitions, Otolaryngology/Ear, Nose & Throat (ENT) Tagged With: Fiagon, Intersect ENT

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy